Hoda Gabriel is a clinical research and development professional with 28 years of experience directing, designing, planning, and successfully executing early and late phase clinical drug programs within the pharmaceutical industry. As well as being the President of Oculus Research, Ms. Gabriel is currently the Sr. Director of Clinical Development at T3D Therapeutics. Prior to her current positions, she held director‐level positions with GlaxoSmithKline and Talecris (now Grifols), where she led several international programs and teams to successful NDA/MAA submissions. Additionally, she founded two independent clinical research companies. Ms. Gabriel has experience in the development of multiple therapeutic areas including CNS, Urology, Metabolic, Cardiovascular, Pain, Dermatology and Peripheral Arterial Disease.
Rosemarie Pladna is a Clinical Operations Director for Oculus Research (OR). She received her BA in Biology and Associate Degree in Nursing at Youngstown State University. Prior to joining OR, she worked in the Pharmaceutical Industry for over 21 years. Rosemarie’s career at GlaxoSmithKline included experience as a Senior Clinical Research Scientist, Clinical Compliance Manager and ultimately an Account Director for R&D Internal Audit. She was the recipient of a Platinum Award for her successful work in hosting FDA inspections in France, Germany and the USA, keeping the company in good standing. She provides guidance to the OR staff with regard to Good Clinical Practice in the conduct of human subject research.